<p>KALA BIO, Inc. (NASDAQ:KALA - 免费报告) 的股票计划在 5 月 11 日星期一市场开盘前进行 1-50 的反向拆分。该反向拆分于 5 月 7 日星期四宣布。股东持有的股份数量将在 5 月 8 日星期五市场收盘后进行调整。</p>
<h2>KALA BIO 价格表现</h2>
<ul>
<li>Kala Pharmaceuticals 在过去一个月上涨了 400%，接下来会怎样？</li>
</ul>
<p>NASDAQ:KALA 的股票在星期四的午盘交易中下跌了 0.03 美元，达到 0.08 美元。该公司交易了 8,127,962 股，而其平均交易量为 6,040,966 股。公司的 50 日移动平均价格为 0.23 美元，200 日移动平均价格为 0.51 美元。该公司的市值为 7724 万美元，市盈率为-0.02，贝塔值为-2.23。KALA BIO 的 52 周低点为 0.08 美元，52 周高点为 20.60 美元。</p>
<p>KALA BIO (NASDAQ:KALA - 获取免费报告) 最近于 4 月 15 日星期三发布了其财报。公司报告每股收益（EPS）为 0.86 美元，超出市场共识预期的-0.17 美元，超出幅度为 1.03 美元。</p>
<h2>分析师评级变动</h2>
<p>另外，Weiss Ratings 在 3 月 27 日星期五的研究报告中重申了对 KALA BIO 股票的 “卖出（e+）” 评级。一位投资分析师给予该股票买入评级，四位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，共识目标价为 20.38 美元。</p>
<p><strong>获取我们对 KALA BIO 的最新分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Virtu Financial LLC 在第四季度购买了价值约 48,000 美元的 KALA BIO 新股份。XTX Topco Ltd 在第二季度购买了价值约 62,000 美元的 KALA BIO 新股份。Jane Street Group LLC 在第四季度购买了价值约 80,000 美元的 KALA BIO 新股份。Geode Capital Management LLC 在第二季度将其在 KALA BIO 的持股增加了 2.8%。Geode Capital Management LLC 目前拥有 56,367 股该公司的股票，价值 268,000 美元，此前在上个季度又购买了 1,534 股。最后，Baker BROS. Advisors LP 在第四季度将其在 KALA BIO 的持股增加了 83.1%。Baker BROS. Advisors LP 目前拥有 1,804,055 股该公司的股票，价值 1,003,000 美元，此前在上个季度又购买了 818,962 股。24.61% 的股票目前由机构投资者持有。</p>
<h2>KALA BIO 公司简介</h2>
<p>(获取免费报告)</p>
<p>KALA Bio NASDAQ: KALA 是一家商业阶段的生物制药公司，专注于开发和商业化用于眼科疾病的新疗法。该公司的专有表面电荷基础纳米颗粒递送平台旨在增强治疗药物在眼表面的渗透和滞留。这项技术是其主要产品 Eysuvis (KPI-121 1.0%) 的基础，该产品是 FDA 批准的用于短期缓解与过敏性结膜炎相关的眼部瘙痒的局部类固醇。</p>
<p>除了其已批准的疗法外，KALA Bio 还在推进一系列针对炎症和退行性眼病的研究药物候选者。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 KALA BIO 更好</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 KALA BIO 吗？</h2>
<p>在你考虑 KALA BIO 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 KALA BIO 并不在名单上。</p>
<p>虽然 KALA BIO 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Kala制药

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

<p>KALA BIO, Inc.（纳斯达克代码：KALA）将在 5 月 11 日进行 1 比 50 的反向股票拆分，此公告于 5 月 7 日发布。股票调整将在 5 月 8 日市场收盘后进行。该股票近期波动较大，交易价格降至 0.08 美元，市值为 7724 万美元。分析师的评级各异，包含一项买入、四项持有和一项卖出。KALA BIO 专注于开发眼科疾病的治疗方案，包括其获得 FDA 批准的产品 Eysuvis</p>

<p>KALA BIO, Inc. (NASDAQ:KALA - Free Report)'s stock is scheduled to reverse split before the market opens on Monday, May 11th. The 1-50 reverse split was announced on Thursday, May 7th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, May 8th.</p>
<div class="lb-trans"><p>KALA BIO, Inc. (NASDAQ:KALA - 免费报告) 的股票计划在 5 月 11 日星期一市场开盘前进行 1-50 的反向拆分。该反向拆分于 5 月 7 日星期四宣布。股东持有的股份数量将在 5 月 8 日星期五市场收盘后进行调整。</p>
</div><h2>KALA BIO Price Performance</h2>
<div class="lb-trans"><h2>KALA BIO 价格表现</h2>
</div><ul>
<li>Kala Pharmaceuticals Up 400% In The Past Month, What's Next ?</li>
</ul>
<div class="lb-trans"><ul>
<li>Kala Pharmaceuticals 在过去一个月上涨了 400%，接下来会怎样？</li>
</ul>
</div><p>Shares of NASDAQ:KALA traded down $0.03 during mid-day trading on Thursday, reaching $0.08. 8,127,962 shares of the company traded hands, compared to its average volume of 6,040,966. The company's 50 day moving average price is $0.23 and its 200-day moving average price is $0.51. The firm has a market cap of $77.24 million, a PE ratio of -0.02 and a beta of -2.23. KALA BIO has a 52 week low of $0.08 and a 52 week high of $20.60.</p>
<div class="lb-trans"><p>NASDAQ:KALA 的股票在星期四的午盘交易中下跌了 0.03 美元，达到 0.08 美元。该公司交易了 8,127,962 股，而其平均交易量为 6,040,966 股。公司的 50 日移动平均价格为 0.23 美元，200 日移动平均价格为 0.51 美元。该公司的市值为 7724 万美元，市盈率为-0.02，贝塔值为-2.23。KALA BIO 的 52 周低点为 0.08 美元，52 周高点为 20.60 美元。</p>
</div><p>KALA BIO (NASDAQ:KALA - Get Free Report) last released its earnings results on Wednesday, April 15th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $1.03.</p>
<div class="lb-trans"><p>KALA BIO (NASDAQ:KALA - 获取免费报告) 最近于 4 月 15 日星期三发布了其财报。公司报告每股收益（EPS）为 0.86 美元，超出市场共识预期的-0.17 美元，超出幅度为 1.03 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Separately, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of KALA BIO in a research note on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Hold&#34; and a consensus target price of $20.38.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 3 月 27 日星期五的研究报告中重申了对 KALA BIO 股票的 “卖出（e+）” 评级。一位投资分析师给予该股票买入评级，四位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，共识目标价为 20.38 美元。</p>
</div><p><strong>Get Our Latest Analysis on KALA BIO</strong></p>
<div class="lb-trans"><p><strong>获取我们对 KALA BIO 的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of KALA BIO during the fourth quarter valued at approximately $48,000. XTX Topco Ltd bought a new stake in shares of KALA BIO in the second quarter worth about $62,000. Jane Street Group LLC purchased a new stake in shares of KALA BIO in the fourth quarter worth about $80,000. Geode Capital Management LLC increased its stake in KALA BIO by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock worth $268,000 after acquiring an additional 1,534 shares during the last quarter. Finally, Baker BROS. Advisors LP grew its holdings in shares of KALA BIO by 83.1% in the fourth quarter. Baker BROS. Advisors LP now owns 1,804,055 shares of the company's stock valued at $1,003,000 after purchasing an additional 818,962 shares in the last quarter. 24.61% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Virtu Financial LLC 在第四季度购买了价值约 48,000 美元的 KALA BIO 新股份。XTX Topco Ltd 在第二季度购买了价值约 62,000 美元的 KALA BIO 新股份。Jane Street Group LLC 在第四季度购买了价值约 80,000 美元的 KALA BIO 新股份。Geode Capital Management LLC 在第二季度将其在 KALA BIO 的持股增加了 2.8%。Geode Capital Management LLC 目前拥有 56,367 股该公司的股票，价值 268,000 美元，此前在上个季度又购买了 1,534 股。最后，Baker BROS. Advisors LP 在第四季度将其在 KALA BIO 的持股增加了 83.1%。Baker BROS. Advisors LP 目前拥有 1,804,055 股该公司的股票，价值 1,003,000 美元，此前在上个季度又购买了 818,962 股。24.61% 的股票目前由机构投资者持有。</p>
</div><h2>KALA BIO Company Profile</h2>
<div class="lb-trans"><h2>KALA BIO 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>KALA Bio NASDAQ: KALA is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company's proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.</p>
<div class="lb-trans"><p>KALA Bio NASDAQ: KALA 是一家商业阶段的生物制药公司，专注于开发和商业化用于眼科疾病的新疗法。该公司的专有表面电荷基础纳米颗粒递送平台旨在增强治疗药物在眼表面的渗透和滞留。这项技术是其主要产品 Eysuvis (KPI-121 1.0%) 的基础，该产品是 FDA 批准的用于短期缓解与过敏性结膜炎相关的眼部瘙痒的局部类固醇。</p>
</div><p>Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.</p>
<div class="lb-trans"><p>除了其已批准的疗法外，KALA Bio 还在推进一系列针对炎症和退行性眼病的研究药物候选者。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than KALA BIO</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 KALA BIO 更好</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in KALA BIO Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 KALA BIO 吗？</h2>
</div><p>Before you consider KALA BIO, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 KALA BIO 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KALA BIO wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 KALA BIO 并不在名单上。</p>
</div><p>While KALA BIO currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 KALA BIO 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

KALA BIO Stock Scheduled to Reverse Split on Monday, May 11th (NASDAQ:KALA)

Market Beat

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

Virtu Finc

KALA BIO 股票计划于 5 月 11 日星期一进行反向拆股（NASDAQ:KALA）